Evidence map›Paper›PMID 41353240›Full record

ArticleScientific reports2025

Combined inhibition of NAD synthesis and C-terminal binding protein cooperatively induces cell death and inhibits growth of high grade serous ovarian carcinoma.

Kranthi Kumar Chougoni, Jacqueline West, Nicholette St Martin, Diana Dcona, Istem Kose, Nari Kim, Martin M Dcona, Ronny Drapkin, Joseph W Carlson, Ann E Walts and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kranthi Kumar ChougoniHoag Family Cancer Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA.
Jacqueline WestDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Nicholette St MartinDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Diana DconaUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Istem KoseKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Nari KimUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Martin M DconaUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Ronny DrapkinPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Joseph W CarlsonUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Ann E WaltsDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sandra OrsulicDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Keith C EllisDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.
Steven R GrossmanHoag Family Cancer Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. steven.grossman@hoag.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transcriptional scaffolds C-terminal Binding Proteins (CtBP) 1 and 2 are overexpressed and act as oncogenic dependencies in multiple cancers but importantly encode a chemically targetable dehydrogenase domain. CtBP promotes survival of high grade serous ovarian carcinoma (HGSOC) cells by repressing expression of Death Receptors (DR) 4 and 5, which activate caspase 8-dependent apoptosis. We have previously developed a series of substrate competitive CtBP dehydrogenase inhibitors active in multiple cell and preclinical solid tumor models. In the current study, we validated CtBP1 and 2 overexpression in a longitudinal series of primary and metastatic/recurrent HGSOC cases. Our lead CtBP dehydrogenase inhibitor, JW-98, induced apoptosis and exhibited variable single agent IC

Indexed as

Alcohol OxidoreductasesCystadenocarcinoma, SerousDNA-Binding ProteinsNADOvarian NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationCo-Repressor ProteinsFemaleHumansMiceXenograft Model Antitumor AssaysAlcohol OxidoreductasesCo-Repressor ProteinsCTBP2 protein, humanC-terminal binding proteinDNA-Binding ProteinsNAD

Identifiers

PMID41353240
PMCPMC12789539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.